Skip to main content
. 2017 Mar 7;8:240. doi: 10.3389/fimmu.2017.00240

Figure 2.

Figure 2

Treatment with AS101 decreases crescent formation in crescentic glomerulonephritis. Treatment protocol was as described in Figure 1 with one modification. Experimental groups were as follows: daily i.p. injection with PBS without αGBM administration (control); daily injection with PBS of αGBM-induced rats (αGBM only) and two treatment groups of αGBM-induced rats with daily i.p. injections of AS101 (100 μg/rat) starting 1 day before (–1), or 6 days after (+6) the αGBM administration. Groups were tested weekly until week 4. Treatment starting at day 3 (+3) was tested only at week 4. Renal Histology was performed on kidney sections for detection of crescents formation on week 2 (A). The percentage of glomeruli with crescents was evaluated in 100 glomeruli/rat on weeks 1, 2, 3, and 4 after αGBM administration (B). Data are presented as mean ± SE of 8 rats/group for each time point. #p < 0.01 increase vs. control; *p < 0.05 decrease vs. αGBM. **p < 0.01 decrease vs. αGBM. The two-way ANOVA was used.